CELLULAR INTERACTIONS RESPONSIBLE FOR DEVELOPMENT, MAINTENANCE, AND STRENGTH OF THE SKELETON
With
Prof Natalie A Sims, PhD.
Deputy Director, St. Vincent’s Institute,
Melbourne, Australia
RESEARCHER PROFILE
Filmed in Melbourne, Australia | May 2025
Professor Sims directs the Bone Cell Biology and Disease Unit at St. Vincent’s Institute of Medical Research and is a Professorial Fellow at The University of Melbourne and Australian Catholic University.
She leads a team who studies the cellular interactions responsible for development, maintenance, and strength of the skeleton. She completed her PhD at the University of Adelaide, followed by postdoctoral work at the Garvan Institute in Sydney then at Yale School of Medicine, in New Haven, Connecticut, where she studied the role of the estrogen receptor in regulating bone structure.
She returned to Australia in 2001 to set up a laboratory at St. Vincent’s Hospital and SVI. Her laboratory studies the cellular interactions responsible for development, maintenance, and strength of the skeleton, including the IL-6 family of cytokines, using genetically altered mouse models, in vitro system and human specimens. She has published more than 140 peer reviewed original research articles, 48 peer reviewed review articles and commentaries, and 20 published chapters; H index of 64 (Scopus); more than 13,500 career citations.
Her work has been recognised by awards from her colleagues internationally, including the International Bone and Mineral Society Herbert A Fleisch Award (2013) and the American Society of Bone and Mineral Research (ASBMR) Fuller Albright Award (2010) and Paula Stern Award (2020).
She is a Deputy Editor of the Journal of Bone and Mineral Research and serves on the Editorial Board of the Journal of Biological Chemistry. She has served as President of the Australia and New Zealand Bone and Mineral Society and is currently Executive Secretary of the International Federation of Musculoskeletal Research Societies.
Source: Supplied
-
World-first clinical trial improves patient outcomes for kidney transplants (2023)
A world-first clinical trial conducted at the Royal Adelaide Hospital (RAH) and at hospitals across Australia and New Zealand has identified the best fluid treatment to reduce the risk of patients requiring dialysis after a kidney transplant.
Around one in three people who receive a kidney transplant suffer delayed graft function, which means the transplant doesn’t work immediately and they require dialysis.
The lead-author of the study, was Royal Adelaide Hospital Nephrologist and University of Adelaide researcher, Dr Michael Collins.
-
Indigenous Australian health and ear disease
Professor Kelvin Kong feels incredibly fortunate to lead a fulfilling life surrounded by his loved ones. With a demonstrated history of service in the health industry, he brings a wealth of expertise across various sectors including clinical research, medical education, surgery, paediatrics, health policy, and Indigenous education. Kelvin started his university, residing at New College in 1992, which brings him fond memories. Graduating from medicine from the University of NSW, Kelvin continued his studies and became a fellow of the Royal Australasian College of Surgeons (RACS) and Australian Society of Otolaryngology, head & neck Society (ASOHNS).
-
Treatment pathways for chronic plantar heel pain
Jason Rogers is a Tasmanian physiotherapist clinician-researcher with a longstanding interest in improving musculoskeletal foot and ankle conditions. He completed his PhD at the Menzies Institute for Medical Research at the University of Tasmania in 2022 investigating the clinical and imaging factors associated with a common foot complaint known as chronic plantar heel pain.
